1-4 of 4
Mark S. Marshall
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy

Free
Jian Du, Lei Yan, Raquel Torres, Xueqian Gong, Huimin Bian, Carlos Marugán, Karsten Boehnke, Carmen Baquero, Yu-Hua Hui, Sonya C. Chapman, Yanzhu Yang, Yi Zeng, Sarah M. Bogner, Robert T. Foreman, Andrew Capen, Gregory P. Donoho, Robert D. Van Horn, Darlene S. Barnard, Jack A. Dempsey, Richard P. Beckmann, Mark S. Marshall, Li-Chun Chio, Yuewei Qian, Yue W. Webster, Amit Aggarwal, Shaoyou Chu, Shobha Bhattachar, Louis F. Stancato, Michele S. Dowless, Phillip W. Iversen, Jason R. Manro, Jennie L. Walgren, Bartley W. Halstead, Matthew Z. Dieter, Ricardo Martinez, Shripad V. Bhagwat, Emiko L. Kreklau, Maria Jose Lallena, Xiang S. Ye, Bharvin K.R. Patel, Christoph Reinhard, Gregory D. Plowman, David A. Barda, James R. Henry, Sean G. Buchanan, Robert M. Campbell
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12): 2207–2219.
https://doi.org/10.1158/1535-7163.MCT-18-0529
Published: 02 December 2019
View article titled, Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy
Open the PDF for Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy in another window
Includes: Supplementary data
Journal Articles

LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms

Free
Constance King, H. Bruce Diaz, Samuel McNeely, Darlene Barnard, Jack Dempsey, Wayne Blosser, Richard Beckmann, David Barda, Mark S. Marshall
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (9): 2004–2013.
https://doi.org/10.1158/1535-7163.MCT-14-1037
Published: 02 September 2015
View article titled, LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms
Open the PDF for LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms in another window
Includes: Supplementary data
Journal Articles

Abstract A108: LY2606368, a second generation Chk1 inhibitor, inhibits growth of ovarian carcinoma xenografts either as monotherapy or in combination with standard-of-care agents.

Free
Samuel C. McNeely, Teresa F. Burke, Sara DurlandBusbice, Darlene S. Barnard, Mark S. Marshall, Aimee K. Bence, Richard P. Beckmann
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A108.
https://doi.org/10.1158/1535-7163.TARG-11-A108
Published: 12 November 2011
View article titled, Abstract A108: LY2606368, a second generation Chk1 inhibitor, inhibits growth of ovarian carcinoma xenografts either as monotherapy or in combination with standard-of-care agents.
Journal Articles

Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-κB pathway in pancreatic carcinoma cells

Free
Michele T. Yip-Schneider, Harikrishna Nakshatri, Christopher J. Sweeney, Mark S. Marshall, Eric A. Wiebke, C. Max Schmidt
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2005) 4 (4): 587–594.
https://doi.org/10.1158/1535-7163.MCT-04-0215
Published: 12 April 2005
View article titled, Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-κB pathway in pancreatic carcinoma cells
Open the PDF for Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-κB pathway in pancreatic carcinoma cells in another window